Cite
HARVARD Citation
Yamamoto, N. et al. (2021). Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung cancer. pp. 20-24. [Online].